CIR

Immuron Clinical Trials Update

Retrieved on: 
Friday, December 22, 2023
Spore, Clostridioides difficile, ASX, Immuron, Principal, Diarrhea, FDA, NMRC, Campylobacter, IMC, Johns Hopkins University, Trial of the century, MD, Agriculture, Clinical trial, GLP, Volunteering, Escherichia, Escherichia coli, CIR, CHIM, Patient, Monash University, Safety, JHU, Clostridioides, Pharmaceutical industry

MELBOURNE, Australia, Dec. 22, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to provide shareholders and the market with an update on the company’s clinical development portfolio.

Key Points: 
  • The NMRC has recently completed the in-patient stage of the campylobacter challenge clinical study.
  • Headline results from the clinical trial are anticipated to be reported in H2 2024.
  • The Phase 2 clinical trial is designed to evaluate the safety and protective efficacy of the new product manufactured by Immuron compared to a placebo in a controlled human infection model (CHIM).
  • The inpatient challenge phase of the Travelan clinical study led by Principal Investigator Dr Mohamed Al-Ibrahim at the Pharmaron CPC FDA inspected Clinical Research Facility Inpatient Unit located in Baltimore, Maryland US, has been completed.

Immutep Receives A$2.6 million R&D Tax Incentive from French Government

Retrieved on: 
Thursday, December 7, 2023
Immunotherapy, Recherche, ASX, Research, European, IMM, Cancer, Calendar, CIR, Immutep, Eftilagimod alpha

SYDNEY, AUSTRALIA, Dec. 07, 2023 (GLOBE NEWSWIRE) --  Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune diseases, is pleased to announce it has received a €1,595,475 (~ A$2,628,354 ) research and development (R&D) tax incentive payment in cash from the French Government under its Crédit d’Impôt Recherche scheme (CIR).

Key Points: 
  • The “Crédit d’Impôt Recherche” (CIR), meaning “Research Tax Credit”, is a French government tax incentive by which French companies conducting research and development activities in Europe can be reimbursed 30% of their eligible expenditure.
  • Immutep qualifies for the CIR tax incentive through its subsidiary Immutep S.A.S.
  • Immutep also qualifies for cash rebates from the Australian Federal Government’s R&D tax incentive program in respect of expenditure incurred on eligible R&D activities conducted in Australia.
  • As previously announced, in October 2023, the company received an A$1.13 million cash rebate from the Australian Federal Government’s R&D tax incentive program for the eligible R&D activities conducted in financial year 2022.

Immuron Announces First Patients Enrolled in Campylobacter Challenge Clinical Study

Retrieved on: 
Monday, December 4, 2023
ASX, Immuron, Principal, IBS, Diarrhea, NMRC, ETEC, Campylobacter, Disease, IMC, Trial of the century, Johns Hopkins University, MD, Clinical trial, Enterotoxigenic Escherichia coli, Infection, Morale, CIR, CHIM, Gastroenteritis, Safety, JHU, Judgement, Pharmaceutical industry

MELBOURNE, Australia, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce that the US Naval Medical Research Command (NMRC) has initiated the clinical evaluation of a new oral therapeutic targeting Campylobacter and Enterotoxigenic Escherichia coli (ETEC) developed in collaboration with Immuron. The NMRC has prioritized the clinical development of the study to evaluate the efficacy of the new therapeutic product to prevent infectious diarrhea caused by Campylobacter.

Key Points: 
  • The NMRC has prioritized the clinical development of the study to evaluate the efficacy of the new therapeutic product to prevent infectious diarrhea caused by Campylobacter.
  • The clinical study is being led by Principal Investigator Dr Kawsar Talaat, MD at the Johns Hopkins University (JHU) Center for Immunization Research (CIR) Inpatient Unit, located at the JHU Bayview Medical Campus, Baltimore, Maryland.
  • The dosing, challenge and the in-patient stage of the study is anticipated to be completed by the third week of December 2023.
  • The estimated study completion date (last participant, last visit) is June 2024 with headline results from the clinical trial expected to be reported in 2H 2024.

EQS-News: Allianz increases revenues by 4.5% to 36.5 billion euros - Group affirms full-year outlook

Retrieved on: 
Thursday, December 28, 2023
Roe, 3Q, Solvency, CSM, Economics, Trust, NBM, Asset management, Alpha, VOYA, Insurance, Allianz, Financial instrument, CIR, Growth, Internal, Finance, VNB, EPS, Environment, Chemical

We confirm with confidence our operating profit target of 14.2 billion euros, plus or minus 1 billion euros.

Key Points: 
  • We confirm with confidence our operating profit target of 14.2 billion euros, plus or minus 1 billion euros.
  • Favorable foreign currency translation effects of 34.4 billion euros and net inflows of 10.5 billion euros were largely offset by market effects of 37.1 billion euros.
  • 9M 2023: Operating revenues decreased by 5.9 percent to 5.8 billion euros mainly as a result of lower AuM-driven revenues.
  • Third-party assets under managementwere 1.670 trillion euros as of September 30, 2023, up by 35 billion euros from the end of 2022.

EQS-News: GRENKE significantly increases earnings in Q3 2023

Retrieved on: 
Tuesday, December 26, 2023
Environment, Growth, EUR, Interest, CM2, CIR, Film industry

Consolidated Group net profit also rose sharply year-on-year by 18.0% to EUR 24.0 million (Q3 2022: EUR 20.3 million).

Key Points: 
  • Consolidated Group net profit also rose sharply year-on-year by 18.0% to EUR 24.0 million (Q3 2022: EUR 20.3 million).
  • Earnings per share equalled EUR 0.53 (Q3 2022: EUR 0.50).
  • The CM2 margin remained stable at 16.5% in the third quarter of 2023 (Q3 2022: 16.4%) despite a further rise in interest rates.
  • As of September 30, 2023, the GRENKE Group’s total assets amounted to EUR 7.1 billion (December 31, 2022: EUR 6.4 billion).

Kyriba’s Quarterly Currency Impact Report: FX Volatility Spikes to $29.14 Billion in Earnings Impacts

Retrieved on: 
Tuesday, November 21, 2023
Professional Services, Data Management, Technology, Finance, Software, Consulting, Risk, FX, China State Construction Engineering, EUR, CFOS, CAD, EPS, Engineering, CNY, CIR, Cryptocurrency, Arms industry, Rolling (metalworking), Bank, Video game

Kyriba’s latest Currency Impact Report (CIR) shows multinational companies experienced over $29bn in total impacts to earnings from currency volatility in the second quarter of this year.

Key Points: 
  • Kyriba’s latest Currency Impact Report (CIR) shows multinational companies experienced over $29bn in total impacts to earnings from currency volatility in the second quarter of this year.
  • The CIR studies the quarterly impacts of foreign exchange (FX) exposures among 1,700 multinational companies based in North America and Europe with at least 15 percent of overseas revenue.
  • “This data is a clear signal to global organizations with significant overseas exposure that currency volatility continues to erode value.
  • The average earnings per share (EPS) impact reported by publicly traded North American companies in Q2 2023 was $0.05.

EQS-News: Abivax announces the filing of an amended registration statement, including an estimated initial public offering price range

Retrieved on: 
Thursday, October 26, 2023
Therapy, Cyprus Securities and Exchange Commission, Exercise, KREO, SVB Securities, American depositary receipt, Code, State Street, Sale, Telephone, Form, European Parliament, Patient, CD, Varick Street, CEST, Research, Application, 2nd Floor, ADS, European, Note, AMF, Council, Morgan Stanley, UC, Private, Attention, CIR, The Heights, Prospectus, Document, KC, Commercial code, Security (finance), Cryptocurrency, Pharmaceutical industry, Abivax, EU, Euronext Paris

Abivax announces the filing of an amended registration statement, including an estimated initial public offering price range

Key Points: 
  • Abivax announces the filing of an amended registration statement, including an estimated initial public offering price range
    The issuer is solely responsible for the content of this announcement.
  • Offering”) and a concurrent offering of ordinary shares in certain jurisdictions outside of the United States (the “European Private Placement”, and together, the “Global Offering”).
  • The Company’s ordinary shares are listed on the regulated market of Euronext Paris (“Euronext Paris”) under the symbol “ABVX”.
  • Morgan Stanley and Leerink Partners are acting as joint global coordinators for the proposed Global Offering and joint bookrunners for the U.S. Offering.

EQS-News: Abivax announces the pricing of its Initial Public Offering on the Nasdaq Global Market 

Retrieved on: 
Thursday, October 26, 2023
Compartment, Therapy, Chapter Three, Exercise, KREO, Central bank, SVB Securities, American depositary receipt, Code, State Street, Sale, Telephone, Form, Patient, CD, Varick Street, CEST, Research, 2nd Floor, ADS, Note, Chapter Five, AMF, Morgan Stanley, UC, ISIN, Private, Attention, CIR, European Central Bank, The Heights, Risk, Prospectus, Document, KC, Commercial code, Security (finance), Cryptocurrency, Pharmaceutical industry, Euronext Paris

Offering”) and a concurrent offering of 1,626,040 ordinary shares in certain jurisdictions outside of the United States to certain investors (the “European Private Placement” and together with the U.S. Offering, the “Global Offering”).

Key Points: 
  • Offering”) and a concurrent offering of 1,626,040 ordinary shares in certain jurisdictions outside of the United States to certain investors (the “European Private Placement” and together with the U.S. Offering, the “Global Offering”).
  • The Global Offering is expected to close on October 24, 2023, subject to the satisfaction of customary closing conditions.
  • The ADSs have been approved for listing on the Nasdaq Global Market and are expected to begin trading on October 20, 2023 under the ticker symbol “ABVX”.
  • Morgan Stanley and Leerink Partners are acting as joint global coordinators for the proposed Global Offering and joint bookrunners for the U.S. Offering.

EQS-News: Q3 2023: DWS Progresses with Continued Net Inflows and Stable Revenues in Challenging Market Environment

Retrieved on: 
Thursday, October 26, 2023
Adjustment, Asset, DWS, Bank, ESG, ETF, Om, Doctor of Philosophy, Holding, CIR, DWS Group, Risk management, Marketing, Executive Committee, Biozentrum University of Basel, Head, Allianz Global Investors, EUR, University, Bank of China, AML, Julius Baer Group, Investment, Order, University of St. Gallen, ETP, Capital, Film industry, Commercial property, Lithium, Financial adviser, Q2, Active, Q3, European, Cash

In the first nine months of the year, DWS generated net inflows (ex cash) of EUR 20.8 billion, including Cash of EUR 17.3 billion.

Key Points: 
  • In the first nine months of the year, DWS generated net inflows (ex cash) of EUR 20.8 billion, including Cash of EUR 17.3 billion.
  • Assets under Management increased marginally in Q3 2023 to EUR 860 billion as net inflows and positive exchange rate movements slightly exceeded the negative impact from market developments.
  • The adjusted profit before tax was 6 percent lower in Q3 compared to Q2, while net income increased by 2 percent.
  • Adjusted revenues were virtually stable at EUR 666 million in Q3 2023 (Q2 2023: EUR 668 million).

Immutep receives ~A$1.13 million R&D Tax Incentive

Retrieved on: 
Wednesday, October 25, 2023
ASX, Immutep, Research, R, CIR, 2009 Australian federal budget, AusIndustry, IMM, European, Calendar, Health insurance

SYDNEY, AUSTRALIA, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or the “Company”), is pleased to announce that it has received a A$1,134,882 cash rebate from the Australian Federal Government’s R&D tax incentive program. The cash rebate provided in respect of expenditure incurred on eligible R&D activities conducted in the 2022 fiscal year, mainly related to the Company’s TACTI-002 and TACTI-003 clinical study using its lead compound eftilagimod alpha (“efti” or “IMP321”), conducted in Australia.

Key Points: 
  • SYDNEY, AUSTRALIA, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or the “Company”), is pleased to announce that it has received a A$1,134,882 cash rebate from the Australian Federal Government’s R&D tax incentive program.
  • Due to the Advance Finding, both Immutep’s Australian and overseas research and development activities related to the TACTI-002 and TACTI-003 Australian sites were eligible for the R&D Tax Incentive.
  • Immutep also receives the French CIR tax incentive through its subsidiary Immutep S.A.S in respect of expenditure incurred on eligible R&D activities conducted in the European Union.
  • Immutep will apply the non-dilutive funding towards furthering its current active clinical trial programs for its lead product candidate, efti.